The upgrade follows four consecutive quarters of above-industry-average revenue growth, driven by the biopharma end market, and the addition of a new CEO.
The company posted second quarter revenues of $494.7 million, up from $481.8 million in Q2 2014 and beating the average Wall Street estimate of $481.7 million.
Waters has signed an instrument control agreement with Agilent and recognized Chang Gung University as a Center of Innovation Partner.
The conference was relatively light on new mass spec launches, with many vendors focusing instead on more targeted applications of existing technology.
The company posted revenues of $460.4 million compared to $430.5 million in Q1 2014, beating the average Wall Street estimate of $445.3 million.
The amendment to a 2013 debt financing agreement will increase revolving commitments to $1.3 billion, extend maturity of loans, and adjust interest rates and fees.
Interest in detection directly from specimens and antibiotic resistance is leading some researchers to look at methods likeREIMSand MRM-MS.
The agency approved the Acquity UPLC I-Class IVD/Xevo TQ-S IVD LC-MS for clinical analysis of various targets.
Many of the meeting's proteomics presentations concerned not so much mass spec analysis itself as the refinement of processes and workflows leading up to it.
PerkinElmer's liquid and gas chromatography portfolio will be standardized on Waters' Empower Software.
NPR says the explosion and fire earlier this week at a Russian lab that stores dangerous pathogens revives the question of whether such samples should be kept.
According to Wired, Nebula Genomics is providing a way for people to get their genomes sequenced anonymously.
A 26-year-old woman tells Cosmopolitan about learning her APOE status at a young age.
In Science journals this week: a functional genomic screen uncovers drug combination that increases KRAS inhibitor efficacy in aggressive lung cancer, and more.